Serum amyloid A impairs the antiinflammatory properties of HDL

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 266-281

  Han, Chang Yeop ^a   Tang, Chongren ^a   Guevara, Myriam E ^b   Wei, Hao ^a   Wietecha, Tomasz ^b   Shao, Baohai ^a   Subramanian, Savitha ^a   Omer, Mohamed ^a   Wang, Shari ^a   O'Brien, Kevin D ^b   Marcovina, Santica M ^a   Wight, Thomas N ^c   Vaisar, Tomas ^a   De Beer, Maria C ^d   De Beer, Frederick C ^d   Osborne, William R ^b   Elkon, Keith B ^b   Chait, Alan ^a  

^a Diabetes and Obesity Center of Excellence   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PALMITIC ACID; PROTEOGLYCAN; SERUM AMYLOID A; SILVER NITRATE; TOLL LIKE RECEPTOR 4; C REACTIVE PROTEIN; CHOLESTEROL; REACTIVE OXYGEN METABOLITE;

3T3 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CCL2 GENE; CELL MEMBRANE; CELL SURFACE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SAA3 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; 3T3-L1 CELL LINE; ANIMAL; C57BL MOUSE; METABOLISM; PHYSIOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; C-REACTIVE PROTEIN; CHOLESTEROL; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; SERUM AMYLOID A PROTEIN; SILVER NITRATE; TOLL-LIKE RECEPTOR 4;

EID: 84956609542     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83475     Document Type: Article

References (86)

1. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring). 2007;15(12):2875-2888.
2. Grundy SM. Cardiovascular and metabolic risk factors: how can we improve outcomes in the highrisk patient? Am J Med. 2007;120(9 suppl 1):S3-S8.
3. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81-87.
4. Schmidt AM. Insulin resistance and metabolic syndrome: mechanisms and consequences. Arterioscler Thromb Vasc Biol. 2012;32(8):1753.
5. Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep. 2008;10(1):32-38.
6. Khovidhunkit W, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169-1196.
7. Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 2010;8(3):413-423.
8. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764-772.
9. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep. 2007;9(6):493-498.
10. Murphy AJ, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28(11):2071-2077.
11. Sun Y, et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res. 2009;104(4):455-465.
12. Kunitake ST, Jarvis MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A. 1992;89(15):6993-6997.
13. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044(2):275-283.
14. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15(11):1987-1994.
15. Nicholls SJ, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111(12):1543-1550.
16. Umemoto T, et al. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP binding cassette G-1, and scavenger receptor B-1. Circ Res. 2013;112(10):1345-1354.
17. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep. 2006;8(5):405-411.
18. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18(4):427-434.
19. Ansell BJ, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751-2756.
20. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103(18):2283-2288.
21. Van Lenten BJ, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758-2767.
22. McMahon M, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2541-2549.
23. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265(2):501-523.
24. van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol. 2007;18(2):147-151.
25. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem. 1986;261(21):9644-9651.
26. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20(3):763-772.
27. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36(5):1058-1065.
28. Tsun JG, Shiu SW, Wong Y, Yung S, Chan TM, Tan KC. Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. Atherosclerosis. 2013;231(2):405-410.
29. Vaisar T, et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015;56(8):1519-1530.
30. Tolle M, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94(1):154-162.
31. Shao B, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem. 2005;280(7):5983-5993.
32. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23(3):447-454.
33. Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res. 2010;51(7):1849-1858.
34. Shao B, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux enhanced HDL oxidation by myeloperoxidase. Circ Res. 2014;114(11):1733-1742.
35. Pennathur S, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004;279(41):42977-42983.
36. Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem. 2012;287(9):6375-6386.
37. Park S, Park NY, Valacchi G, Lim Y. Calorie restriction with a high-fat diet effectively attenuated inflammatory response and oxidative stress-related markers in obese tissues of the high diet fed rats. Mediators Inflamm. 2012;2012:984643.
38. Alemany M. Regulation of adipose tissue energy availability through blood flow control in the metabolic syndrome. Free Radic Biol Med. 2012;52(10):2108-2119.
39. Das SK, et al. An integrative genomics approach identifies activation of thioredoxin/thioredoxin reductase-1-mediated oxidative stress defense pathway and inhibition of angiogenesis in obese nondiabetic human subjects. J Clin Endocrinol Metab. 2011;96(8):E1308-E1313.
40. Dullaart RP, de Boer JF, Annema W, Tietge UJ. The inverse relation of HDL anti-oxidative functionality with serum amyloid A is lost in metabolic syndrome subjects. Obesity (Silver Spring). 2013;21(2):361-366.
41. Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol. 1998;141(4):929-942.
42. Wabitsch M, et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord. 2001;25(1):8-15.
43. De Beer MC, et al. Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein Edeficient mice. Arterioscler Thromb Vasc Biol. 2014;34(2):255-261.
44. Kim MH, de Beer MC, Wroblewski JM, Webb NR, de Beer FC. SAA does not induce cytokine production in physiological conditions. Cytokine. 2013;61(2):506-512.
45. de Beer MC, et al. Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res. 2010;51(11):3117-3125.
46. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276(20):16683-16689.
47. Lee JY, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003;44(3):479-486.
48. Wong SW, Kwon MJ, Choi AM, Kim HP, Nakahira K, Hwang DH. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem. 2009;284(40):27384-27392.
49. Chiba T, et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol. 2011;31(6):1326-1332.
50. O'Brien KD, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998;98(6):519-527.
51. Han CY, et al. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 2007;56(9):2260-2273.
52. Rosenson RS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905-1919.
53. Dagher G, Donne N, Klein C, Ferre P, Dugail I. HDL-mediated cholesterol uptake and targeting to lipid droplets in adipocytes. J Lipid Res. 2003;44(10):1811-1820.
54. Yvan-Charvet L, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837-1847.
55. Schwartz EA, et al. Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol. 2010;30(4):802-808.
56. Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485-498.
57. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.
58. Kip KE, et al. Global inflammation predicts cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. Am Heart J. 2005;150(5):900-906.
59. Ogasawara K, et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis. 2004;174(2):349-356.
60. Johnson BD, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):726-732.
61. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011;22(4):302-307.
62. Stonik JA, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun. 2004;321(4):936-941.
63. van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem. 2005;280(43):35890-35895.
64. Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov. 2009;3(1):73-80.
65. Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int J Inflam. 2011;2011:514623.
66. Vivekanandan-Giri A, et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis. 2013;72(10):1725-1731.
67. McInnes IB, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2013;74(4):694-702.
68. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010;51(8):2058-2073.
69. Heinecke JW. The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk? Nat Med. 2012;18(9):1346-1347.
70. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18(9):1344-1346.
71. Khera AV, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
72. Rohatgi A, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-2393.
73. Han CY, et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes. 2010;59(2):386-396.
74. Webb NR, et al. Adenoviral vector-mediated overexpression of serum amyloid A in apoA-Ideficient mice. J Lipid Res. 1997;38(8):1583-1590.
75. Subramanian S, et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptordeficient mice. Arterioscler Thromb Vasc Biol. 2008;28(4):685-691.
76. Hutchins PM, et al. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem. 2014;60(11):1393-1401.
77. Lin Y, et al. The hyperglycemia-induced inflammatory response in adipocytes: The role of reactive oxygen species. J Biol Chem. 2005;280(6):4617-4626.
78. Han CY, et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol. 2006;26(8):1806-1813.
79. Han CY, et al. NADPH oxidase-derived reactive oxygen species increases expression of monocyte chemotactic factor genes in cultured adipocytes. J Biol Chem. 2012;287(13):10379-10393.
80. Honda A, et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res. 2009;50(2):350-357.
81. Shao B, Heinecke JW. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 2008;440:33-63.
82. Weisgraber KH, Innerarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem. 1978;253(24):9053-9062.
83. Innerarity TL, Pitas RE, Mahley RW. Lipoprotein-receptor interactions. In: Albers JJ, Segrest JP, eds. Plasma Lipoproteins. San Diego, California, USA: Academic Press; 1986.
84. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem. 1977;252(20):7279-7287.
85. Ohno J, Tajima Y, Utsumi N. Binding of wheat germ agglutinin in the matrix of rat tracheal cartilage. Histochem J. 1986;18(10):537-540.
86. O'Brien KD, et al. Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(4):785-790.